CME Information
Accreditation Statement
The School of Medicine of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Statement
The School of Medicine of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure statement
Planners
This activity has been planned and implemented under the sole supervision of the Course Directors, Deborah Stephens, DO, and Kaitlin Morrison, PhD, and the planning committee, Anne Beaven, MD, and Natalie Grover, MD, in association with the UNC Office of Continuing Professional Development (CPD). CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME. Dr. Morrison has no relevant financial relationships with ineligible companies.
Dr. Stephens received consulting fees from AbbVie, AstraZeneca, BeiGene, BMS, Celgene, Genentech, Janssen, Lilly, and Pharmacyclics; and research support from AbbVie, AstraZeneca, BeiGene, Genentech, Merck, and Novartis.
Dr. Beaven received consulting fees from Vittoria Biotherapeutics (ended 12/23) and research support from Genentech.
Dr. Grover held stock in Sangamo; received consulting fees from ADC Therapeutics (ended 6/24), BMS (3/24), Caribou Biosciences (2/23), Genentech, Janssen (9/23), Kite (3/23), Novartis, Ono Pharma (12/23), Regeneron, Seagen (7/23); and research support from Affimed, BMS, Cabaletta, Poseida, and Regeneron.
These financial relationships have been mitigated through a combination of divestment and the appointment of co-planners with different or no relevant financial relationships.
Speakers
For the speakers who are also planners, please see above.
Dr. Byrd held stock in Eilean Therapeutics, Kurome, and Vincerx Pharma; received consulting fees from AbbVie, AstraZeneca, Eilean Therapeutics, Kartos, Kurome, Newave, Orange Grove Bio, Orbimed, and Vincerx Pharma; and received research support from Eilean Therapeutics, Newave, Orange Grove Bio, and Orbimed.
Dr. Dittus received research grants from AstraZeneca, Genentech, and Seagen.
Dr. Friedberg has no relevant financial relationships.
Dr. Hu received consulting fees from AbbVie (ended 2/24), ADC Therapeutics (11/24), Bristol Myers Squibb (10/24), Caribou Biosciences (2/24), Genentech (11/24), Kite (5/24), Pfizer (9/24), and Regeneron (1/24); and research support from Artiva Biotherapeutics, AstraZeneca, Caribou Biosciences, Celgene (1/24), CRISPR Therapeutics, Genentech, ImmPACT Bio, Morphosys AG, Newave, and Repare Therapeutics (10/24).
Dr. Jensen received consulting fees from Abbie (ended 12/24) and Cardinal Health (ended 10/24).
Dr. Shadman held stock in Koi Biotherapeutics; received speaker fees from Janssen (ended 2/23); receives consulting fees from AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Genentech, Genmab, Janssen, Kite Pharma, Merck, Morphosys/Incyte, and Nurix; and received research grants from AbbVie, AstraZeneca, BeiGene, Genentech, Genmab, Morphosys/Incyte, Mustang Bio, and Vincerx.
Dr. Smith has no relevant financial relationships.